Allergic rhinitis is the most prevalent chronic allergic disease in children. Although it is not life-threatening, it can have a significantly detrimental effect on a child's quality of life, and it may exacerbate a number of common comorbidities, including asthma and sinusitis. The Allergic Rhinitis and its Impact on Asthma guidelines, an evidence-based algorithm for the treatment of allergic rhinitis, advocate the use of antihistamines for the treatment of the broad spectrum of the disease. However, first-generation antihistamines are associated with a number of adverse events, including central nervous system impairment and anticholinergic and cardiovascular effects. Moreover, these agents have not been rigorously tested in the pediatric population. Nevertheless, first-generation antihistamines remain the most frequently prescribed agents in this class of drugs. This is despite the fact that the second-generation antihistamines are largely free of the undesirable side effects associated with their predecessors and the fact that they have been shown to be effective in relieving allergic rhinitis symptoms in children in a number of large-scale clinical trials. Therefore, when selecting an antihistamine for a child, it would be prudent to consider the full range of antihistamines and to base the selection of a particular drug on its efficacy, onset and duration of action, and safety profile.
References
1.
Management of Allergic and Nonallergic Rhinitis. Summary, Evidence Report/Technology Assessment: Number 54, May 2002. Rockville, Md.: U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. www.ahrq.gov/clinic/epcsums/rhinsum.htm (accessed Feb. 2, 2005).
FaginJ, FriedmanR, FiremanP.Allergic rhinitis. Pediatr Clin North Am1981;28:797–806.
4.
VuurmanEF, van VeggelLM, UiterwijkMM, Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy1993;71:121–6.
5.
MarshallPS, ColonEA. Effects of allergy season on mood and cognitive function. Ann Allergy1993;71:251–8.
6.
JuniperEF, GuyattGH, DolovichJ.Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol1994;93:413–23.
7.
MeltzerEO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol2001;108(1 suppl):S45–53.
8.
BousquetJ, Van CauwenbergeP, KhaltaevN.Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol2001;108(5 suppl): S147–334.
9.
SettipaneRA. Complications of allergic rhinitis. Allergy Asthma Proc1999;20:209–13.
10.
FrederickJM, WarnerJO, JessopWJ, Effect of a bed covering system in children with asthma and house dust mite hypersensitivity. Eur Respir J1997;10:361–6.
11.
TerreehorstI, HakE, OostingAJ, Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med2003;349:237–46.
12.
CasaleTB, BlaissMS, GelfandE, First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol2003;111:S835–42.
13.
WahnU, MeltzerEO, FinnAFJr., Fexofenadine is efficacious and safe in children (aged 6–11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol2003;111:763–9.
14.
BonerAL, MiglioranziP, RichelliC, Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis. Allergy1989;44:437–41.
15.
LutskyBN, KloseP, MelonJ, A comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of 3- to 6-year-old children with seasonal allergic rhinitis. Clin Ther1993;15:855–65.
16.
PearlmanDS, LumryWR, WinderJA, NoonanMJ. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: Arandomized, double-blind, placebo-controlled study. Clin Pediatr (Phila)1997;36:209–15.
17.
TinkelmanD, KempJ, MitchellD, Treatment of seasonal allergic rhinitis in children with cetirizine or chlorpheniramine: A multicenter study. Pediatr Asthma Allergy Immunol1996;10:9–17.
18.
AllegraL, PaupeJ, WiesemanHG, BaeldeY.Cetirizine for seasonal allergic rhinitis in children aged 2–6 years. A double-blind comparison with placebo. Pediatr Allergy Immunol1993;4:157–61.
19.
SimonsFE, SilasP, PortnoyJM, Safety of cetirizine in infants 6 to 11 months of age: A randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol2003;111:1244–8.
SimonsFE, McMillanJL, SimonsKJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: Suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol1990;86(4 Pt 1):540–7.
22.
RivestJ, DespontinK, GhysL, Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine. Dermatologica1991;183:208–11.
23.
GrantJA, RiethuisenJM, MoulaertB, DeVosC.A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol2002;88:190–7.
24.
FrossardN, PurohitA, KovacsS, Fexofenadine is superior to loratadine and desloratadine in onset of action of histamine-induced wheal and flare inhibition. Ann Allergy Asthma Immunol2003;90:124.
25.
PurohitA, N'GomAS, DeslandesB, Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction. Ann Allergy Asthma Immunol2004;93:562–67.
26.
SimonsFE, SimonsKJ. Peripheral H1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol1997;79:530–2.
27.
DayJH, BriscoeM, RafeiroE, Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: Confirmation of a test system. Ann Allergy Asthma Immunol2001;87:474–81.
28.
SimonsFE, SemusM, GoritzSS, SimonsKJ. H1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr Allergy Immunol2003;14:207–11.
29.
LitovitzT, HolmK, BaileyK, SchmitzB.Demographic profile of exposure cases by generic category of substances and products: Nonpharmaceuticals. Annual Report of the American Association of Poison Control Centers National Data Collection System. 1991:477–89.
30.
GoetzCM, LopezG, DeanBS, KrenzelokEP. Accidental childhood death from diphenhydramine overdosage. Am J Emerg Med1990;8:321–2.
31.
RidoutSM, TariqSM, Cetirizine overdose in a young child. J Allergy Clin Immunol1997;99(6 Pt 1):860–1.
32.
VuurmanEF, van VeggelLM, SandersRL, Effects of semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Ann Allergy Asthma Immunol1996;76:247–52.
33.
ReillyMC, TannerA, MeltzerEO. Work, classroom and activity impairment instruments: Validation studies in allergic rhinitis. Clin Drug Invest1996;11:278–88.
34.
BenderBG, McCormickDR, MilgromH.Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine. J Pediatr2001;138:656–60.
35.
WeilerJM, BloomfieldJR, WoodworthGG, Effects of fexofenadine, diphenhydramine, and alcohol on drivingperformance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med2000;132:354–63.
36.
NicholsonAN, HandfordAD, TurnerC, StoneBM. Studies on performance and sleepiness with the H1 -antihistamine, desloratadine. Aviat Space Environ Med2003;74:809–15.
37.
MeltzerEO, ScheinmannP, RosadoPinto JE, Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis—A pooled analysis of three studies. Pediatr Allergy Immunol2004;15:253–60.
38.
GraftDF, BernsteinDI, GoldsobelA, Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol2001;87:22–6.
39.
NgKH, ChongD, WongCK, Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: A randomized, double-blind, placebo-controlled comparative study. Pediatrics2004;113e116–21.
40.
HindmarchI, ShamsiZ.Antihistamines: Models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy1999;29(suppl 3): 133–42.
41.
ShamsiZ, HindmarchI.Sedation and antihistamines: A review of inter-drug differences using proportional impairment ratios Hum Psychopharmacol2000; 15(S1):S3–S30.
42.
SnyderSH, SnowmanAM. Receptor effects of cetirizine. Ann Allergy1987;59(6 Pt 2):4–8.
43.
SimonsFE, BergmanJN, WatsonWT, SimonsKJ. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol1996;98(6 Pt 1):1062–4.
44.
SalmunLM, HerronJM, BanfieldC, The pharmacokinetics electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Clin Ther2000;22:613–21.
45.
DiepgenTL. Long-term treatment with cetirizine of infants with atopic dermatitis: A multi-country, double-blind, randomized placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol2002;13:278–86.
